Synergistic protection of astragalus polysaccharides and matrine against ulcerative colitis and associated lung injury in rats

Table 1 Body weight of rats in various groups

Group	n	0 wk	n	2 wk	n	4 wk
Normal	10	414.00 ± 29.28	10	467.50 ± 21.44	10	507.60 ± 49.21
Model	10	355.90 ± 25.60b	10	413.10 ± 27.91b	10	461.30 ± 37.54
Salazopyrine control			10	420.70 ± 35.29b	11	451.91 ± 38.31b
Matrine treatment			13	429.23 ± 38.04a	12	458.83 ± 45.36a
APS treatment			13	443.62 ± 45.06	13	486.92 ± 55.67
Monomer mixture			13	426.92 ± 30.74b	12	489.75 ± 32.06

^aP < 0.05 and

^bP < 0.01 vs normal group. APS: Astragalus polysaccharides.

Table 2 Disease activity indexes of rats in various groups

Group	n	0 wk	n	2 wk	n	4 wk
Normal	10	0.00 ± 0.00	10	0.00 ± 0.00	10	0.00 ± 0.00
Model	10	3.00 ± 0.59b	10	1.67 ± 0.90b	10	1.13 ± 0.63b
Salazopyrine control			10	0.80 ± 0.53a	11	0.36 ± 0.35
Matrine treatment			13	0.51 ± 0.48ac	12	0.33 ± 0.45
APS treatment			13	0.67 ± 0.47b	13	0.41 ± 0.34a
Monomer mixture			13	0.56 ± 0.48ac	12	0.56 ± 0.48ac

^aP < 0.05 and

^bP < 0.01 vs normal group;

^cP < 0.05 vs model group. APS: Astragalus polysaccharides.

Table 3 Colon mucosal damage indexes of rats in various groups

Group	n	0 wk	n	2 wk	n	4 wk
Normal	10	0.00 ± 0.00	10	0.00 ± 0.00	10	0.00 ± 0.00
Model	10	6.70 ± 1.89b	10	6.40 ± 1.78b	10	4.70 ± 2.06b
Salazopyrine control			10	3.90 ± 2.23b	11	4.00 ± 2.24b
Matrine treatment					12	1.83 ± 1.59ac
APS treatment					13	2.33 ± 1.97a
Monomer mixture			11	0.56 ± 0.48ac	12	1.92 ± 1.73ac

^aP < 0.05 and

^bP < 0.01 vs normal group;

^cP < 0.05 vs model group. APS: Astragalus polysaccharides.